Search

everythinglearnresearchcommunity

for

Search:↓

Pyrilutimide, a treatment for hair loss; it's effectiveness compared to other treatments such as Finasteride and RU58841; and some users’ experiences with the treatment.

The user had a failed hair transplant in 2018, didn't use medication, and experienced severe depression from further hair loss. They started treatment in 2022 with 0.5mg daily finasteride, 2.5mg oral minoxidil, 1ml daily topical minoxidil, and are considering low dose RU58841 and dermarolling.

The user is experiencing hair loss after a hair transplant and is considering using fluridil (Eucapil) and possibly alfatradiol as treatments, as they couldn't tolerate finasteride or minoxidil. The manufacturer of Eucapil confirmed they won't produce higher concentrations due to lack of efficacy.

Users discuss alternatives to DHT blockers for hair loss, suggesting minoxidil, microneedling, natural DHT blockers, and scalp massages. Some explore RU58841, ketoconazole, hair transplants, and hair systems due to side effects from finasteride and dutasteride.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Pyrilutamide Phase 2 results are expected in June 2022, with hopes for a better alternative to current treatments.

Hair loss treatments and the user's plan to start using Pyrilutamide, a combination of Minoxidil and Finasteride.

First people receive Pyrilutamide on March 19th, 2022 for hair loss treatment. Users discuss obtaining the drug, its patent, and potential group buys.

Hair loss treatments, specifically about the effectiveness of RU58841 compared to Pyrilutamide. Molecular weights and side effects were discussed in terms of efficacy and cost-effectiveness.

A 41-year-old male has been using a combination of treatments for hair regrowth, including finasteride, minoxidil, a laser cap, ketoconazole shampoo, and rosemary oil, with some progress noted. He is maintaining his current regimen in hopes of a future miracle drug while considering hair transplants and other treatments like dutasteride and copper peptides.

The conversation is about creating a higher concentration of the newly FDA-approved hair loss treatment, Clascoterone (Winlevi), through compounding pharmacies and possibly organizing group purchases. Some users are unfamiliar with Winlevi and are asking for an explanation of the drug.

The user is considering starting pyrilutamide before a scheduled hair transplant, having previously used oral minoxidil and finasteride with worsening results. They also tried dutasteride, which worsened their hair and made their skin oily.

The conversation discusses hair regrowth using 5mg oral Minoxidil, 1.25mg Finasteride, weekly dermarolling, and hormone replacement therapy (HRT) with estrogen and testosterone blockers. The user reports positive results and attributes significant improvement to HRT.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Anageninc stopped selling KX-826 (Pyrilutamide) due to a cease and desist letter from Kintor, but this may indicate promising study results and a potential 2024 release.

The group buy for CB-03-01, a topical anti-androgen for hair loss, was postponed and refunded due to issues with the product's form and solubility. The product, also known as Breezula, is an alternative to finasteride with fewer side effects, but its official release is delayed until 2021.

Akinfenrawr experienced negative side effects from oral finasteride and RU58841, and is seeking alternative hair loss treatments. They discuss various options, including raloxifene, oral dutasteride, liposomal finasteride, Breezula, Pyrilutamide, SM04554, and sulforaphane, but have concerns about efficacy, availability, and cost.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Bayer dismissed HMI-115 due to focus shift away from women's health.

User considers trying Pyrilutamide for hair loss and itch relief. Another user shares positive experience with Pyrilutamide, no side effects.

The conversation discusses a new liposomal topical finasteride from Hasson and Wong, available in Canada and Italy, soon in the US, costing $40/month. It claims to reduce scalp DHT by 50% without affecting serum DHT, potentially benefiting those who can't tolerate oral finasteride or RU58841.

The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.

The user underwent a hair transplant in Turkey and has been using a topical solution with 5% minoxidil and 0.0025% finasteride, along with Ket 2% shampoo and derma rolling, to maintain hair status. They are uncertain about improvements, noting thicker non-transplanted hair, and are considering increasing medication frequency to enhance results.

The user has been taking small doses of Finasteride, mixed with Stemoxydine, which has helped maintain their existing hair but not regrow new hair. They're considering dissolving the Finasteride in high-alcohol content drinks for easier administration and are seeking opinions on this method.

A user shared their hair regrowth progress using Dutasteride, topical Minoxidil, Spironolactone, and Estradiol Valerate injections as part of hormone replacement therapy for transitioning. They experienced significant hair improvement and personal satisfaction but caution against this approach for non-transitioning individuals due to irreversible changes.

The user applied 0.005% topical finasteride, minoxidil, tretinoin, caffeine, and ketoconazole shampoo for four months but saw no hair regrowth. Some users suggested increasing the finasteride dose or trying alternative treatments like clascoterone, pyrilutamide, or RU58841.

The conversation humorously discusses starting treatments like finasteride, dutasteride, RU58841, and oral minoxidil for hair loss. It highlights the challenges and experiences associated with these treatments.

ABS-201, a prolactin receptor blocker, shows promise in reversing hair loss and graying, with early success in macaques. Current treatments like finasteride, minoxidil, and RU58841 are still widely used, but new options like PP405 are eagerly anticipated.

The user's progress in treating their hair loss using finasteride, minoxidil, vitamins, and microneedling, with one person suggesting to wait six more months before considering a hair transplant. The other person agreed that a hair transplant would be nice.

Treatments for hair loss, focusing on Fluridil/Topilutamide (Eucapil), Finasteride and RU58841 (Alfatradiol). The user reported that the Fluridil seemed to work well but had side effects of testicle ache, decreased mood and sex drive.

VDPHL01 shows faster and stronger hair growth compared to standard minoxidil, with no major side effects reported. Users discuss combining it with other treatments like dutasteride and finasteride for better results, while expressing skepticism about the effectiveness of PP405.

The conversation is about using pyrilutamide and RU58841 as topical solutions to prevent hair loss. Pyrilutamide is considered safer but less potent than RU58841, which some users find effective despite potential side effects like heart palpitations.

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.